Mevacor reverses atherosclerosis in patients without CHD history -- Merck ACAPS study.
MERCK MEVACOR LABELING INCLUDES STUDY OF USE IN PATIENTS WITH NO CHD, Merck announced April 3. The Asymptomatic Carotid Artery Progression Study showing that Mevacor reverses atherosclerosis in patients with no history of coronary heart disease was approved for inclusion in labeling by FDA on Feb. 9. Merck announced the labeling change following public release of the Bristol-Myers Squibb CARE study, which concluded that Pravachol reduces heart disease in post-MI patients with average cholesterol levels ("The Pink Sheet" April 1, T&G-10).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth